TY - JOUR
T1 - Age Cutoff for Early-Onset Parkinson's Disease
T2 - Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease
AU - the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease
AU - Mehanna, Raja
AU - Smilowska, Katarzyna
AU - Fleisher, Jori
AU - Post, Bart
AU - Hatano, Taku
AU - Pimentel Piemonte, Maria Elisa
AU - Kumar, Kishore Raj
AU - McConvey, Victor
AU - Zhang, Baorong
AU - Tan, Eng King
AU - Savica, Rodolfo
AU - Savica, Rodolfo
AU - Tan, Eng King
AU - Mehanna, Raja
AU - Smilowska, Katarzyna
AU - Marras, Connie
AU - Ross, Owen
AU - Kumar, Kishore
AU - Fleisher, Jori
AU - McConvey, Victor
AU - Hatano, Taku
AU - Wu, Yih Ru
AU - Zhang, Baorong
AU - Alcalay, Roy
AU - Merola, Aristide
AU - Post, Bart
AU - Salari, Mehri
N1 - Funding Information:
Raja Mehanna is on the speaker bureau for TEVA, Adamas Pharmaceuticals, Kyowa Kirin, and Sunovion. He has received research grants from Global Kinetic Corporation, Northera, Neurocrine, and Cerevel. Katarzyna Smilowska has nothing to disclose. Jori Fleisher has received royalties from Wolters Klewer Health/UpToDate and honoraria from the Parkinson's Foundation and the Davis Phinney Foundation. She also has the following research support: National Institute of Neurological Disorders and Stroke (NINDS; 1K23NS097615‐01A1 [principal investigator, PI: Fleisher], 5U01NS100610‐05/737SUB U01NS100610 [PI: Leverenz; role: site PI]), National Institute on Aging (NIA; 5P30AG064200‐02 [PI: Hepburn; role: pilot study PI]), Parkinson's Foundation (PF‐COE‐PC‐920660 [role: site palliative care champion], PF‐CORE_2004 [PI: Fleisher], PF‐CORE‐856255 [PI: Fleisher]), PCORI (15963‐PF PCORI [PI: Schroeder, role: collaborative member]), Rush University (Leslie Nan Burridge Faculty Scholar in Parkinson's Disease Research Endowment [PI: Fleisher]; Rush University Center for Excellence in Aging Pilot Grant [PI: Labuschagne; role: coinvestigator]; Rush University Movement Disorders Pilot Grant [PI: Shah‐Zamori; role: coinvestigator]), and private philanthropic support. Bart Post has nothing to disclose. Taku Hatano is employed at Juntendo University School of Medicine and received a grant from the Japan Agency for Medical Research and Development under grant numbers 20dm0107156, 21wm0425015, 21ak0101112, and 21dk0207055; the Japan Society for the Promotion of Science under grant number 21K07424; a grant from Setsuro Fujii Memorial Foundation; TaNeDS; research funds from Daiichi Sankyo TaNeDS Funding Program; speaker's honoraria from Dainippon Sumitomo; Takeda Pharmaceutical Company Co., Ltd.; FP Pharmaceutical Corporation; Kyowa Kirin Co., Ltd.; Ono Pharmaceutical Co., Ltd.; AbbVie GK; Eisai Co., Ltd.; Sanofi K.K.; and Otsuka Pharmaceutical Co., Ltd. Maria Elisa Pimentel Piemonte has nothing to disclose. Kishore Raj Kumar received honoraria from Seqirus, AbbVie Pty Ltd, Research Review Australia Pty Limited; grant funding from the Paul Ainsworth Family Foundation, The Michael J. Fox Foundation, and GP2 (unrelated to the current study); is employed by New South Wales (NSW) Health; and receives royalties from Oxford University Press for first edition. Victor McConvey has nothing to disclose. Baorong Zhang M has nothing to disclose. Eng‐King Tan received honoraria for editorial duties for and grant support from the National Medical Research Council, Singapore. Rodolfo Savica received research support from the NIA, the NINDS, and the Mayo Clinic Small Grants Program National Center for Advancing Translational Sciences and an unrestricted research grant from Acadia Pharmaceuticals Inc. Financial Disclosures for the Previous 12 Months: Neurogenetics (What Do I Do Now) Clinical Parkinsonism Related Disorders
Funding Information:
We thank all the members of the Early Onset Parkinson Disease Task Force for their contribution to this project. The EOPD task force is composed of Rodolfo Savica, MD, PhD (Chair); Eng-King Tan, MD (Co-Chair); Raja Mehanna, MD; Katarzyna Smilowska, MD, PhD; Connie Marras, MD, PHD; Owen Ross, PhD; Kishore Kumar, MBBS, PhD, FRACP; Jori Fleisher, MD, MSCE; Victor McConvey, RN, MACN; Taku Hatano, MD, PhD; Yih-Ru Wu, MD; Baorong Zhang, MD; Roy Alcalay, MD; Aristide Merola, MD, PhD; Bart Post, MD, PhD; and Mehri Salari, MD.
Publisher Copyright:
© 2022 International Parkinson and Movement Disorder Society.
PY - 2022/10
Y1 - 2022/10
N2 - Background: Early-onset Parkinson's disease (EOPD)/young-onset Parkinson's disease (YOPD) is defined as Parkinson's disease (PD) with an age at onset (AAO) after age 21 years but before the usual AAO for PD. Consensus is lacking, and the reported maximal age for EOPD/YOPD has varied from 40 to 60 years, leading to a lack of uniformity in published studies and difficulty in harmonization of data. EOPD and YOPD have both been used in the literature, somewhat interchangeably. Objective: To define the nomenclature and AAO cutoff for EOPD/YOPD. Methods: An extensive review of the literature and task force meetings were conducted. Conclusions were reached by consensus. Results: First, the literature has seen a shift from the use of YOPD toward EOPD. This seems motivated by an attempt to avoid age-related stigmatization of patients. Second, in defining EOPD, 56% of the countries use 50 or 51 years as the cutoff age. Third, the majority of international genetic studies in PD use an age cutoff of younger than 50 years to define EOPD. Fourth, many studies suggest that changes in the estrogen level can affect the predisposition to develop PD, making the average age at menopause of 50 years an important factor to consider when defining EOPD. Fifth, considering the differential impact of the AAO of PD on professional and social life, using 50 years as the upper cutoff for the definition of EOPD seems reasonable. Conclusions: This task force recommends the use of EOPD rather than YOPD. It defines EOPD as PD with AAO after 21 years but before 50 years.
AB - Background: Early-onset Parkinson's disease (EOPD)/young-onset Parkinson's disease (YOPD) is defined as Parkinson's disease (PD) with an age at onset (AAO) after age 21 years but before the usual AAO for PD. Consensus is lacking, and the reported maximal age for EOPD/YOPD has varied from 40 to 60 years, leading to a lack of uniformity in published studies and difficulty in harmonization of data. EOPD and YOPD have both been used in the literature, somewhat interchangeably. Objective: To define the nomenclature and AAO cutoff for EOPD/YOPD. Methods: An extensive review of the literature and task force meetings were conducted. Conclusions were reached by consensus. Results: First, the literature has seen a shift from the use of YOPD toward EOPD. This seems motivated by an attempt to avoid age-related stigmatization of patients. Second, in defining EOPD, 56% of the countries use 50 or 51 years as the cutoff age. Third, the majority of international genetic studies in PD use an age cutoff of younger than 50 years to define EOPD. Fourth, many studies suggest that changes in the estrogen level can affect the predisposition to develop PD, making the average age at menopause of 50 years an important factor to consider when defining EOPD. Fifth, considering the differential impact of the AAO of PD on professional and social life, using 50 years as the upper cutoff for the definition of EOPD seems reasonable. Conclusions: This task force recommends the use of EOPD rather than YOPD. It defines EOPD as PD with AAO after 21 years but before 50 years.
KW - Parkinson's disease
KW - age cutoff
KW - early onset
KW - young onset
UR - http://www.scopus.com/inward/record.url?scp=85137847974&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137847974&partnerID=8YFLogxK
U2 - 10.1002/mdc3.13523
DO - 10.1002/mdc3.13523
M3 - Review article
AN - SCOPUS:85137847974
SN - 2330-1619
VL - 9
SP - 869
EP - 878
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 7
ER -